Please login to the form below

Not currently logged in
Email:
Password:

Questcor appoints SVP corporate strategic development

Michael Aldridge joins from Australian early development company Xenome

US biopharma Questcor Pharmaceuticals has named Michael Aldridge as its first senior VP, corporate strategic development.

His main responsibilities will include identifying potential partnerships and acquisitions for the company, which specialises in developing treatments for difficult-to-treat autoimmune and inflammatory disorders.

These moves could see it expand outside the US with its lead product HP Acthar Gel  (repository corticotropin injection), an injectable drug, which is approved by the FDA in several indications including the treatment of proteinuria in idiopathic types of nephrotic syndrome and the treatment of acute exacerbations of multiple sclerosis in adults.

Development programmes that complement Acthar are also a potential as Questcor looks to expand.

"Michael brings an extensive background in the global biotechnology and pharmaceutical industries that is relevant to Questcor's long term strategic growth and development," said Steve Cartt, chief operating officer of Questcor.

"Our flagship product, Acthar, has proven to be a product of great clinical utility and promise, and the addition of Michael to the Questcor team bolsters our ability to further build our portfolio within a longer term global strategy.”

Aldrige's most recent position was as CEO and managing director of Xenome, an Australia-headquartered early development company.

He has also served as CEO and managing director of Peplin, a company that was acquired by LEO Pharma.

Prior to joining the healthcare industry, Aldridge was an investment banker holding senior positions at firms including Wilson HTM Investment Group, Bear Stearns & Co and Volpe.

30th January 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
certain health

Transforming the way health brands and companies communicate, we deliver creative science led, insight-driven solutions that give award winning results...

Latest intelligence

PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....
Sharing patient stories for World Pulmonary Hypertension Day
For World Pulmonary Hypertension Day and we’re here to help raise awareness of pulmonary hypertension (PH) - a frequently under and misdiagnosed condition. Created in collaboration with the PH patient...